Who is sponsoring NCT00052156?

NCT00052156 is sponsored by CancerVax Corporation.

What condition does NCT00052156 study?

NCT00052156 studies Malignant Melanoma.

What drugs are being tested in NCT00052156?

Interventions: CancerVax vaccine (CANVAXIN).

What is the status of NCT00052156?

NCT00052156 is currently UNKNOWN.

Last reviewed 2005-06-23 · How we verify

A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma

NCT00052156 Phase 3 UNKNOWN

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Details

Lead sponsor	CancerVax Corporation
Phase	Phase 3
Status	UNKNOWN
Enrolment	670

Conditions

Malignant Melanoma

Interventions

CancerVax vaccine (CANVAXIN)

Countries

United States, Australia, Brazil, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Switzerland, United Kingdom